Related Experiment Video
Updated: May 8, 2026
04:04
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
Intracavitary therapeutics for pleural malignancies
Andrew R Haas1, Daniel H Sterman
1Section of Interventional Pulmonology and Thoracic Oncology, Division of Pulmonary, Allergy, and Critical Care, Department of Medicine, University of Pennsylvania Medical Center, Philadelphia, PA, USA.
Clinics in Chest Medicine
|September 3, 2013
Summary
Novel therapies for fatal pleural malignancies show promise. Hyperthermic intrapleural chemotherapy with debulking, intrapleural immunotherapies for early stages, and immunogene therapy combined with surgery offer improved outcomes for pleural cancer.
Area of Science:
- Oncology
- Thoracic Surgery
- Cancer Immunology
Background:
- Pleural malignancies represent a significant unmet medical need due to their invariably fatal nature.
- Current intrapleural (IP) chemotherapy offers limited efficacy in managing these aggressive cancers.
- There is a critical need for innovative therapeutic strategies to improve patient survival and quality of life.
Purpose of the Study:
- To explore the potential of novel therapeutic approaches for pleural malignancies.
- To evaluate the efficacy of hyperthermic intrapleural chemotherapy combined with maximal tumor debulking.
- To assess the role of intrapleural immunotherapies and immunogene therapy in managing pleural cancers.
Main Methods:
- Investigating hyperthermic chemotherapy in conjunction with maximal tumor debulking for intrapleural administration.
- Examining the application of intrapleural immunotherapies, particularly in early-stage pleural malignancy.
- Exploring combination strategies involving debulking surgery, chemotherapy, and intrapleural genetic immunotherapy.
Main Results:
- Hyperthermic intrapleural chemotherapy, combined with maximal tumor debulking, may enhance treatment efficacy.
- Intrapleural immunotherapies show potential for superior effusion control and survival prolongation compared to standard pleurodesis in early-stage disease.
- Combination approaches integrating debulking surgery, chemotherapy, and intrapleural genetic immunotherapy may overcome limitations in treating bulky tumors.
Conclusions:
- Novel therapeutic strategies, including hyperthermic chemotherapy and immunotherapy, hold significant promise for treating pleural malignancies.
- Combination therapies involving surgical debulking, chemotherapy, and genetic immunotherapy present a viable strategy for advanced disease.
- Further research into these advanced intrapleural treatments is warranted to improve outcomes for patients with pleural cancers.
Related Concept Videos
01:30Pleural Disorders: Types and Brief Description
The pleura is a vital part of the respiratory system. It's a double-layered membrane surrounding the lungs and lining the chest cavity. The two layers of the pleura are:
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
01:28Pleural Effusion II: Symptoms and Management
Pleural Effusion Overview
A pleural effusion is the abnormal collection of fluid between the parietal and visceral pleura layers of tissue that form the lining of the lungs and chest cavity. It can occur independently or due to surrounding parenchymal diseases, such as infection, malignancy, or inflammatory conditions.
Clinical Manifestations:
A pleural effusion is the abnormal collection of fluid between the parietal and visceral pleura layers of tissue that form the lining of the lungs and chest cavity. It can occur independently or due to surrounding parenchymal diseases, such as infection, malignancy, or inflammatory conditions.
Clinical Manifestations:
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:27Pneumothorax-II
Pneumothorax is a medical condition defined by the buildup of air in the pleural space between the lungs and the chest wall. This accumulation of air can lead to partial or complete lung collapse, resulting in a range of clinical manifestations. Understanding the clinical presentation and effective management strategies is crucial for healthcare professionals in providing timely and appropriate care to individuals with pneumothorax.
Clinical Manifestations:
Clinical Manifestations:
01:13Pleura of the Lungs
The lungs are nestled in a cavity, shielded by the pleura. The pleura, a form of serous membrane, wraps around each lung. This membrane arrangement consists of two layers: the visceral and parietal pleurae. The visceral pleura lines the surface of the lungIn contrast, the parietal pleura is the outer layer and contacts to the thoracic wall, the mediastinum, and the diaphragm. The hilum is the point of connection between the visceral and parietal layers. The space between the parietal and...